US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pacer WealthShield ETF

32.02

0.0000

Volume:57.00

Turnover:1.83K

Market Cap:30.42M

PE:- -

High:32.02

Open:32.02

Low:32.02

Close:32.02

52wk High:33.71

52wk Low:28.76

Shares:950.00K

Float Shares:800.00K

Volume Ratio:0.04

T/O Rate:0.01%

Dividend:0.47

Dividend Rate:1.47%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Press Release: Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits

MT Newswires Live

Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

Press Release: Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Aardvark Therapeutics Announces Leadership Appointments

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)

Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst

Benzinga_recent_news

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Bright Minds Biosciences Strengthens Advisory Board with PWS Experts

Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study

Press Release: Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors

Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/PWS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PWS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","market":"US","secType":"STK","nameCN":"Pacer WealthShield ETF","latestPrice":32.02,"timestamp":1776877249059,"preClose":32.02,"halted":0,"volume":57,"delay":0,"changeRate":0,"floatShares":800000,"shares":950000,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"04-22 14:16:26 EDT","open":32.02,"high":32.02,"low":32.02,"amount":1825.9607999999998,"amplitude":0,"askPrice":32.05,"askSize":991,"bidPrice":32.03,"bidSize":972,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776888000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"CBOE","adjPreClose":32.02,"sharesOutstanding":950000,"nav":32.04,"aum":30438000,"dividendRate":0.014697,"bidAskSpread":0.000669,"postHourTrading":{"tag":"盘后","latestPrice":32.03,"preClose":32.02,"latestTime":"16:10 EDT","volume":6,"amount":192.12,"timestamp":1776802204724,"change":0.01,"changeRate":0.000312,"amplitude":0},"volumeRatio":0.040283},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PWS\",,,,,undefined,":{"symbol":"PWS","floatShares":800000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.040283,"shares":950000,"dividePrice":0.4706,"high":32.02,"amplitude":0,"preClose":32.02,"low":32.02,"week52Low":28.76,"pbRate":"--","week52High":33.71,"institutionHeld":0,"latestPrice":32.02,"committee":-0.009679,"eps":0,"divideRate":0.014697,"volume":57,"delay":0,"ttmEps":0,"open":32.02,"prevYearClose":32.3237,"prevWeekClose":32.025,"prevMonthClose":32.0135,"prevQuarterClose":32.0135,"fiveDayClose":32,"twentyDayClose":31.644,"sixtyDayClose":33.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PWS\",params:#limit:5,,,undefined,":[{"date":"2026-03-05","symbol":"PWS","amount":0.016362,"announcedDate":"2026-03-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-05","defaultRemindTime":1772721000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-09","payableDate":"2026-03-05","currency":"USD","dateTimestamp":1772686800000,"payDate":"2026-03-09"},{"date":"2025-12-30","symbol":"PWS","amount":0.25921895,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-05","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-05"},{"date":"2025-09-04","symbol":"PWS","amount":0.0796608,"announcedDate":"2025-09-03","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-04","defaultRemindTime":1756992600000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-10","payableDate":"2025-09-04","currency":"USD","dateTimestamp":1756958400000,"payDate":"2025-09-10"},{"date":"2025-06-05","symbol":"PWS","amount":0.116206,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-05","defaultRemindTime":1749130200000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-11","payableDate":"2025-06-05","currency":"USD","dateTimestamp":1749096000000,"payDate":"2025-06-11"},{"date":"2025-03-06","symbol":"PWS","amount":0.059681,"announcedDate":"2025-03-05","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-06","defaultRemindTime":1741271400000,"name":"Pacer WealthShield ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-12","payableDate":"2025-03-06","currency":"USD","dateTimestamp":1741237200000,"payDate":"2025-03-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PWS\",market:\"US\",,,undefined,":[{"executeDate":"2018-03-27","recordDate":"2018-03-28","paymentDate":"2018-03-29","value":0.0522982,"currency":"USD"},{"executeDate":"2018-06-26","recordDate":"2018-06-27","paymentDate":"2018-06-28","value":0.0481106,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-09-27","value":0.1105742,"currency":"USD"},{"executeDate":"2018-12-24","recordDate":"2018-12-26","paymentDate":"2018-12-27","value":0.0682115,"currency":"USD"},{"executeDate":"2019-03-26","recordDate":"2019-03-27","paymentDate":"2019-03-28","value":0.1385698,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PWS\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PWS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625367500","title":"Press Release: Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2625367500","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625367500?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:00","pubTimestamp":1775473200,"startTime":"0","endTime":"0","summary":"VYKAT XR  is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy. Expands Neurocrine's High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA  and CRENESSITY . Establishes a Durable Platform for Long-Term Revenue Growth and Value Creation, Supported by Strong VYKAT XR Intellectual Property Estate Expected to Extend into the mid-2040s. Neurocrine to Host Conference Call at 8:00 AM ET Today to Discuss Transaction. SAN DIEGO and REDWOOD CITY, Calif., April 6, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc.  and Soleno Therapeutics, Inc.  today announced that Neurocrine has entered into a definitive agreement to acquire Soleno for $53.00 per share in cash, representing a total transaction equity value of $2.9 billion.\"Neurocrine is the right strategic partner to expand the reach of VYKAT XR in the Prader-Willi syndrome community given their experience in endocrinology and rare disease an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d77fbd5412928557c10e0692aaf5dc46","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","LU0162691827.USD","LU1267930227.SGD","BK4555","LU0889566641.SGD","BK4139","LU0889565916.HKD","LU2065169927.USD","LU0109394709.USD","LU1571399168.USD","BK4099","BK4604","BK4022","SG9999001440.SGD","NBIX","LU0310800965.SGD","PWS","R","LU1267930490.SGD","LU0052756011.USD","CAH","LU1880398554.USD","SLNO","LU0154245756.USD","LU1880398471.USD","LU0211328371.USD","LU0211327993.USD","LU0006061336.USD","LU2065170008.USD","LU0154245673.USD","BK4175","BK4588","LU0823416689.USD","LU0128525689.USD","LU2065171311.SGD","LU0792757196.USD","LU0072461881.USD","LU1267930813.SGD","LU0320765992.SGD","LU2324357040.USD","LU0154236417.USD","03160","LU2065171402.SGD","LU0310799852.SGD","BK4232","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084925","title":"Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084925","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084925?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:05","pubTimestamp":1774296300,"startTime":"0","endTime":"0","summary":"Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 AR","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260833/0/en/Aardvark-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1267930573.SGD","LU0708994859.HKD","LU0211327993.USD","LU0128525929.USD","HERO","AARD","LU0128526141.USD","CCK","LU1267930490.SGD","LU0310800379.SGD","LU0029874061.USD","BK4126","LU1803068623.USD","LU0029864427.USD","BK4007","LU1892829315.USD","LU0211328371.USD","LU0054578231.USD","LU0310799852.SGD","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618692420","title":"AFT Pharmaceuticals Wins Court of Appeal Case Over Pascomer Profits","url":"https://stock-news.laohu8.com/highlight/detail?id=2618692420","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618692420?lang=en_us&edition=fundamental","pubTime":"2026-03-09 08:16","pubTimestamp":1773015366,"startTime":"0","endTime":"0","summary":"AFT Pharmaceuticals  said that the court of appeal has dismissed PBL Solutions' bid to claim a share of profits from the company's use of its topical skin medicine Pascomer for treating port wine stains , according to a Monday filing with the Australian and New Zealand bourses.The ruling allows the company to retain full profits from Pascomer's use in treating non-orphan conditions like PWS, per the filing.PBL, holding a 35% stake in AFT Orphan Pharmaceuticals, will receive 35% of any profits from Pascomer orphan drug applications, the filing said.PBL and the company will share the appeal costs, and the company does not expect the judgment to materially affect its fiscal year 2026 earnings guidance, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","AFT","PWS","AFP.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614050774","title":"Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR","url":"https://stock-news.laohu8.com/highlight/detail?id=2614050774","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614050774?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:01","pubTimestamp":1772053260,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Feb.  25, 2026  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/25/3244960/0/en/Soleno-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Update-on-U-S-Launch-of-VYKAT-XR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","SLNO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613719807","title":"Press Release: Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719807","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719807?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:30","pubTimestamp":1771936200,"startTime":"0","endTime":"0","summary":"WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 -- $1.04 Billion on Track for Blockbuster Status in Narcolepsy. Recently Completed Settlements with 3 Additional Generic Filers Toward Goal of Securing WAKIX Franchise. Pitolisant GR NDA Submission on Track for Q2 2026; Extends the Pitolisant Franchise into the 2040s. Exploring New Opportunities to Broaden the Pitolisant Franchise Beyond Orphan/Rare into Larger CNS Indications. Potential Best-In-Class Orexin-2 Agonist  Phase 1 Trial Ongoing; Clinical Data Expected in Mid-2026. Fourth Quarter and Full Year 2025 Net Product Revenue for WAKIX. --  Net product revenue for the quarter ended December 31, 2025, was $243.8. million, compared to $201.3 million for the same period in 2024. 8,500 patients in Q4 2025; representing the third consecutive quarter of. --  Net revenue projected between $1.0 billion to $1.04 billion for the","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PWS","BK4022","BK4232","R","HRMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610992780","title":"Aardvark Therapeutics Announces Leadership Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2610992780","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610992780?lang=en_us&edition=fundamental","pubTime":"2026-02-12 21:00","pubTimestamp":1770901200,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Feb.  12, 2026  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutic","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237145/0/en/Aardvark-Therapeutics-Announces-Leadership-Appointments.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS","AARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602037667","title":"Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602037667","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602037667?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:00","pubTimestamp":1767963600,"startTime":"0","endTime":"0","summary":"-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 --  -- FY 2025 preli","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216057/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2025-Net-Product-Revenues-and-Upcoming-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VUS","EC","PWS","BK4201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601089231","title":"Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601089231","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601089231?lang=en_us&edition=fundamental","pubTime":"2026-01-06 20:16","pubTimestamp":1767701760,"startTime":"0","endTime":"0","summary":"BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability  Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/06/3213483/0/en/Bright-Minds-Biosciences-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-BMB-101-in-Patients-with-Absence-Seizures-and-Developmental-and-Encephalopathic-Epilepsie.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591686624","title":"Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2591686624","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591686624?lang=en_us&edition=fundamental","pubTime":"2025-12-13 03:04","pubTimestamp":1765566240,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics gains an Outperform rating as its Phase 3 PWS trial progresses and analysts point to large market potential for ARD-101 and ARD-201.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Diet-And-Dieting--Beauty-Slim-Female-Bod.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/initiation/25/12/49371535/aardvarks-hunger-suppressing-drug-candidate-could-potentially-address-massive-10-billion-market-analyst","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["AARD","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590515385","title":"Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515385","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590515385?lang=en_us&edition=fundamental","pubTime":"2025-12-11 20:30","pubTimestamp":1765456200,"startTime":"0","endTime":"0","summary":"-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy --  -- Promising r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3203809/0/en/Rhythm-Pharmaceuticals-Announces-Preliminary-Data-from-Exploratory-Phase-2-Trial-that-showed-Setmelanotide-Demonstrated-Positive-Efficacy-Signal-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EC","BK4201","PWS","VUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590408558","title":"Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2590408558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590408558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:01","pubTimestamp":1765400460,"startTime":"0","endTime":"0","summary":"BOSTON, Dec.  10, 2025  (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with r","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203492/0/en/Rhythm-Pharmaceuticals-to-Announce-Preliminary-Data-from-Exploratory-Phase-2-Trial-Evaluating-Setmelanotide-in-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4201","VUS","EC","PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584675164","title":"Bright Minds Biosciences Strengthens Advisory Board with PWS Experts","url":"https://stock-news.laohu8.com/highlight/detail?id=2584675164","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584675164?lang=en_us&edition=fundamental","pubTime":"2025-11-18 02:39","pubTimestamp":1763404750,"startTime":"0","endTime":"0","summary":"Bright Minds Biosciences ( ($TSE:DRUG) ) just unveiled an update. Bright Minds Biosciences has expanded its Scientific Advisory Board by adding fou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bright-minds-biosciences-strengthens-advisory-board-with-pws-experts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bright-minds-biosciences-strengthens-advisory-board-with-pws-experts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PWS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584405726","title":"Press Release: Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Experts in Prader-Willi Syndrome (PWS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2584405726","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584405726?lang=en_us&edition=fundamental","pubTime":"2025-11-17 19:50","pubTimestamp":1763380200,"startTime":"0","endTime":"0","summary":"-- Tania Markovic MBBS PhD FRACP; Jennifer L. Miller, MD; Elizabeth Roof, H.S.P., M.A.; and Theresa V. Strong, PhD; distinguished global experts in PWS, will support the Company's PWS program, which was announced on November 6, 2025 --. NEW YORK and VANCOUVER, British Columbia, Nov. 17, 2025  -- Bright Minds Biosciences Inc.    today announced the addition of four global experts in Prader-Willi Syndrome  to its Scientific Advisory Board :. On November 6, 2025, the Company held a KOL event to announce the initiation of its PWS program and the nomination of BMB-105 as a new clinical candidate. A replay of the presentation is available in the Investor section of the Company's website under News & Events.Dr. Jennifer Miller is a Professor in the division","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU2413666426.HKD","LU1721428933.USD","MTD","BK4121","IE00BYQQ9H92.USD","FPWR","LU2413666699.HKD","BK4585","PWS","BK4548","BK4588","BK4533","LU1093756168.USD","BK4139","BK4567","LU0347712357.USD","LU2211817866.USD","DRUG","IE00BFXG0V08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581671769","title":"Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR","url":"https://stock-news.laohu8.com/highlight/detail?id=2581671769","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581671769?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:01","pubTimestamp":1762290060,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Nov.  04, 2025  (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare disease","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180820/0/en/Soleno-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Update-on-U-S-Launch-of-VYKAT-TM-XR.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4215","03160","BK4585","MAA","SLNO","BK4139","PWS","BK4555","TM","BK4604","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578067674","title":"Aardvark Therapeutics Advances PWS Treatment with ARD-101 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2578067674","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578067674?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:19","pubTimestamp":1761603554,"startTime":"0","endTime":"0","summary":"Aardvark Therapeutics, Inc. (($AARD)) announced an update on their ongoing clinical study. Study Overview: Aardvark Therapeutics, Inc. is conductin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-advances-pws-treatment-with-ard-101-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aardvark-therapeutics-advances-pws-treatment-with-ard-101-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AARD","PWS","ARD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2575405141","title":"Press Release: Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405141","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405141?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:00","pubTimestamp":1760356800,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., Oct. 13, 2025  -- Soleno Therapeutics, Inc.  , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of biopharmaceutical finance veteran Mark W. Hahn as an independent director to its Board of Directors and a member of its Audit Committee. Mr. Hahn brings to Soleno's Board nearly 30 years of CFO-level experience and has played a key role in numerous successful product launches, financings, and M&A transactions within the life sciences sector. With the addition of Mr. Hahn, the Soleno Board increases to seven seats.\"I am very pleased to welcome Mark to the Soleno Board as we continue to execute a strong commercial launch of VYKAT XR,\" said Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics. \"With his broad and diverse financial leadership experience, including as CFO of commercial-stage companies developing therapeutics for rare and serious diseases, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TM","SLNO","BK4555","BK4099","BK4588","PWS","BK4604","03160","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2573928291","title":"Aardvark Therapeutics Announces FDA Alignment on Protocol Amendment Expanding Phase 3 HERO Trial Population for Prader-Willi Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2573928291","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573928291?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:00","pubTimestamp":1759924800,"startTime":"0","endTime":"0","summary":"Protocol Expansion to Ages 10+ Aligned with FDA Guidance, Broadening Patient PopulationSAN DIEGO, Oct.  08, 2025  (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/08/3163296/0/en/Aardvark-Therapeutics-Announces-FDA-Alignment-on-Protocol-Amendment-Expanding-Phase-3-HERO-Trial-Population-for-Prader-Willi-Syndrome.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0128525929.USD","LU1267930490.SGD","LU0310799852.SGD","LU0029864427.USD","HERO","LU1267930573.SGD","CCK","LU0029874061.USD","LU0211327993.USD","LU1892829315.USD","PWS","AARD","LU0708994859.HKD","LU0211328371.USD","BK4126","LU0128526141.USD","LU0310800379.SGD","LU1803068623.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":17,"code":"91000000","status":"200"}]}}